Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE: IL13-PE38QQR vs GLIADEL Wafer in Recurrent GBM
NCT00076986Phase 3Completed
- Sponsor
- Insys Therapeutics
- Start
- Feb 2004
- Primary completion
- Mar 2007
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of cintredekin besudotox in glioblastoma multiforme (GBM), sponsored by Insys Therapeutics. Started Feb 2004; status: completed.
02
Drugs
cintredekin besudotox
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00076986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076986.